Last reviewed · How we verify
Advanced PRF
Advanced PRF, marketed by Cairo University, holds a niche position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of clear revenue data, which may affect investment and market confidence.
At a glance
| Generic name | Advanced PRF |
|---|---|
| Sponsor | Cairo University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A-PRF and CGF in Palatal Donor Site Healing (PHASE2)
- Platelet-Derived Growth Factors to Enhance Healing and Reduce Post-Extraction Complications in Smokers (NA)
- Impact of GON PRF on Central Sensitization in Migraine Patients (NA)
- Healing of Mandibular Third Molar Extraction Sockets Using Platelet Concentrates and Photobiomodulation (NA)
- VCMX, PRF and SCTG Treatment in the Gingival Recessions (PHASE3)
- Advanced PRF vs PRF for Gap Filling in Immediate Implants (NA)
- Clinical And Radiographic Evaluation Of Zinc Substituted Nanohyrdoxyappatite Bone Graft And Advanced Platelet Rich Fibrin Block In The Treatment Of Periodontal Intrabony Defects (NA)
- Evaluating Coronally Advanced Flap With Platelet-rich Fibrin Membrane and Chorion Membrane for Gingival Recession (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |